Global Liquid Biopsy Market Analysis, 2020

Rising Incidences of Cancer Cases Expected to Spur the Growth of the Global Liquid Biopsy Market

The liquid biopsy is an advanced cancer diagnostic test that uses bio-fluids such as blood, plasma, and urine for detecting cancer cells that are circulating in the blood.

Global Liquid Biopsy Market Analysis, 2020 research report depicts a deep-dive market analysis of statistics of Global Liquid Biopsy market, which consists of regional and country-wise market size, market forecast, CAGR market segmentation, market shares of diverse regions and countries, market share of various end-users, applications, product type, technologies, competitive benchmarking, etc.

Market Opportunities

According to this research report titled “Global Liquid Biopsy Market Analysis, 2020”, the Global Liquid Biopsy market is anticipated to grow at a CAGR of around 26% during 2021-26F. The liquid biopsy is used to determine the most ideal cancer therapy for the patient and helps the doctor to track how a patient is responding to treatment and to check whether cancer has returned or not. The robust enhancements in NSG technology, surge in the clinical trials for the development of these tests, coupled with burgeoning cancer cases and a paradigm shift toward noninvasive procedures are some of the key drivers proliferating the growth of the global liquid biopsy market.

Market Segmentation

Automotive Segment Acquired the Considerable Market Share

Based on Circulating Biomarkers, Circulating Tumor Cells (CTCs) segment is expected to grow at a high rate in the Global Liquid Biopsy Market in 2020. The CTC's liquid biopsy tests are used to look for whole tumor cells found in the bloodstream. The rising in CTCs in a patient’s bloodstream leads to cancer progression, while a decrease leads to cancer remission. Thus, this is anticipated to drive the growth of the Liquid Biopsy market globally in the near future as stated in the research report “Global Liquid Biopsy Market Analysis, 2020”.

Impact of COVID-19

Steady growth in the liquid biopsy market has been witnessed in the COVID-19 pandemic and it is used to improve cancer screening and care during COVID-19. Moreover, the rising partnerships among the companies to develop commercialize saliva-based liquid biopsy tests for head and neck cancers, COVID-19 testing and other viral diseases are projected to upsurge the growth of the market in the near future.

Competitive Landscape

According to the publisher, the key players with a considerable market share in the Global Liquid Biopsy market include Bio-Rad Laboratories, Biocept Inc, Abcodia Ltd, Chronix Biomedical, Epic Sciences Inc, Hoffmann-La Roche AG, Cynvenio Biosystems, Inc., GUARDANT HEALTH, INC, Illumina, Inc., NeoGenomics Laboratories, Inc., Menarini Silicon Biosystems, Inc., Qiagen N.V., Thermo Fisher Scientific, Personal Genome Diagnostics, Inc., Qiagen N.V., etc.

Key Questions Answered in the Market Research Report:

1. What are the key overall market statistics or market estimates (Market Overview, Market Size- By Value, Forecast Numbers, Market Segmentation, Market Shares) of the Global Liquid Biopsy Market?
2. What is the region-wise industry size, growth drivers, and challenges key market trends?
3. What are the key innovations, technology upgrades, opportunities, regulations in the Global Liquid Biopsy Market?
4. Who are the key competitors or market players and how they perform in the Global Liquid Biopsy Market based on the competitive benchmarking matrix?
5. What are the key results derived from the market surveys conducted during the course of the Global Liquid Biopsy Market study?

1. Introduction

1.1. Product Definition
1.2. Research Process
1.3. Market Segmentation
1.4. Assumptions

2. Preface3. Executive Summary4. Impact of COVID-19 on Global Liquid Biopsy Market

5. Global Liquid Biopsy Market Venture Capital Ecosystem

5.1. Financing By Key Investors
5.2. Financing Recipient Wise Details

6. Global Liquid Biopsy Market Outlook, 2016-2026F

6.1. Market Size & Analysis
6.1.1. Revenues
6.2. Market Share & Analysis
6.2.1. By Work Process
6.2.1.1. Sample Preparation
6.2.1.2. Library Preparation
6.2.1.3. Sequencing
6.2.1.4. Data Analysis
6.2.2. By Technology
6.2.2.1. PCR
6.2.2.1.1. RT-PCR
6.2.2.1.2. dPCR
6.2.2.1.3. Multiplex PCR
6.2.2.1.4. Others
6.2.2.2. NGS
6.2.2.3. FISH
6.2.2.4. Other Technologies
6.2.3. By Usage
6.2.3.1. RUO
6.2.3.2. Clinical
6.2.4. By Sample Type
6.2.4.1. Blood
6.2.4.2. Urine
6.2.4.3. Saliva
6.2.4.4. CerebroSpinal Fluid
6.2.5. By Products
6.2.5.1. Test /Services
6.2.5.2. Kits and Consumables
6.2.5.3. Instruments
6.2.6. By Circulating Biomarkers
6.2.6.1. Circulating Tumor Cells
6.2.6.2. Cell-free DNA
6.2.6.3. Circulating Cell-Free RNA
6.2.6.4. Exosomes and Extracellular Vesicles
6.2.6.5. Others
6.2.7. By Disease Type
6.2.7.1. Lung Cancer
6.2.7.2. Breast Cancer
6.2.7.3. Prostate Cancer
6.2.7.4. Colorectal Cancer
6.2.7.5. Melanoma
6.2.7.6. Other Cancers
6.2.7.7. Non-Oncology Disorders
6.2..8. By Clinical Application
6.2.8.1. Treatment Monitoring
6.2.8.2. Prognosis and Recurrence Monitoring
6.2.8.3. Treatment Selection
6.2.8.4. Diagnosis and Screening
6.2.9. By Region
6.2.9.1. North America
6.2.9.2. South America
6.2.9.3. Europe
6.2.9.4. Middle East & Africa
6.2.9.5. Asia-Pacific
6.2.10. By Company
6.2.10.1. Competition Characteristics
6.2.10.2. Market Share & Analysis
6.2.10.2.1. 2018
6.2.10.2.2. 2019
6.2.10.2.3. 2020
6.2.10.3. Competitive Matrix

7. North America Liquid Biopsy Market Outlook, 2016-2026F

7.1. Market Size & Analysis
7.1.1. Revenues
7.2. Market Share & Analysis
7.2.1. By Technology
7.2.2. By Usage
7.2.3. By Sample Type
7.2.4. By Products
7.2.5. By Circulating Biomarkers
7.2.6. By Disease Type
7.2.7. By Clinical Applications
7.2.8. By Country
7.2.8.1. The US Liquid Biopsy Market Outlook, 2016-2026F
7.2.8.1.1. Market Size & Analysis
7.2.8.1.1.1. Revenues
7.2.8.1.2. Market Share & Analysis
7.2.8.1.2.1. By Circulating Biomarkers
7.2.8.1.2.2. By Disease Type
7.2.8.1.2.3. By Clinical Applications
7.2.8.2. Canada Liquid Biopsy Market Outlook, 2016-2026F
7.2.8.2.1. Market Size & Analysis
7.2.8.2.1.1. Revenues
7.2.8.2.2. Market Share & Analysis
7.2.8.2.2.1. By Circulating Biomarkers
7.2.8.2.2.2. By Disease Type
7.2.8.2.2.3. By Clinical Applications
7.2.8.3. Mexico Liquid Biopsy Market Outlook, 2016-2026F
7.2.8.3.1. Market Size & Analysis
7.2.8.3.1.1. Revenues
7.2.8.3.2. Market Share & Analysis
7.2.8.3.2.1. By Circulating Biomarkers
7.2.8.3.2.2. By Disease Type
7.2.8.3.2.3. By Clinical Applications

8. South America Liquid Biopsy Market Outlook, 2016-2026F

8.1. Market Size & Analysis
8.1.1. Revenues
8.2. Market Share & Analysis
8.2.1. By Technology
8.2.2. By Usage
8.2.3. By Sample Type
8.2.4. By Products
8.2.5. By Circulating Biomarkers
8.2.6. By Disease Type
8.2.7. By Clinical Applications
8.2.8. By Country
8.2.9.
8.2.10. Brazil Liquid Biopsy Market Outlook, 2016-2026F
8.2.10.1. Market Size & Analysis
8.2.10.1.1. Revenues
8.2.10.2. Market Share & Analysis
8.2.10.2.1. By Product & Service
8.2.10.2.2. By Circulating Biomarker
8.2.10.2.3. By Technology
8.2.10.2.4. By Sample Type
8.2.10.2.5. By Application
8.2.10.2.6. By Clinical Application

9. Europe Liquid Biopsy Market Outlook, 2016-2026F

9.1. Market Size & Analysis
9.1.1. Revenues
9.2. Market Share & Analysis
9.2.1. By Technology
9.2.2. By Usage
9.2.3. By Sample Type
9.2.4. By Products
9.2.5. By Circulating Biomarkers
9.2.6. By Disease Type
9.2.7. By Clinical Applications
9.2.8. By Country
9.2.8.1. Germany Liquid Biopsy Market Outlook, 2016-2026F
9.2.8.1.1. Market Size & Analysis
9.2.8.1.1.1. Revenues
9.2.8.1.2. Market Share & Analysis
9.2.8.1.2.1. By Circulating Biomarkers
9.2.8.1.2.2. By Disease Type
9.2.8.1.2.3. By Clinical Applications
9.2.8.2. France Liquid Biopsy Market Outlook, 2016-2026F
9.2.8.2.1. Market Size & Analysis
9.2.8.2.1.1. Revenues
9.2.8.2.2. Market Share & Analysis
9.2.8.2.2.1. By Circulating Biomarkers
9.2.8.2.2.2. By Disease Type
9.2.8.2.2.3. By Clinical Applications
9.2.8.3. The United Kingdom Liquid Biopsy Market Outlook, 2016-2026F
9.2.8.3.1. Market Size & Analysis
9.2.8.3.1.1. Revenues
9.2.8.3.2. Market Share & Analysis
9.2.8.3.2.1. By Circulating Biomarkers
9.2.8.3.2.2. By Disease Type
9.2.8.3.2.3. By Clinical Applications
9.2.8.4. Italy Liquid Biopsy Market Outlook, 2016-2026F
9.2.8.4.1. Market Size & Analysis
9.2.8.4.1.1. Revenues
9.2.8.4.2. Market Share & Analysis
9.2.8.4.2.1. By Circulating Biomarkers
9.2.8.4.2.2. By Disease Type
9.2.8.4.2.3. By Clinical Applications
9.2.8.5. Spain Liquid Biopsy Market Outlook, 2016-2026F
9.2.8.5.1. Market Size & Analysis
9.2.8.5.1.1. Revenues
9.2.8.5.2. Market Share & Analysis
9.2.8.5.2.1. By Circulating Biomarkers
9.2.8.5.2.2. By Disease Type
9.2.8.5.2.3. By Clinical Applications

10. Middle East & Africa Liquid Biopsy Market Outlook, 2016-2026F

10.1. Market Size & Analysis
10.1.1. Revenues
10.2. Market Share & Analysis
10.2.1. By Technology
10.2.2. By Usage
10.2.3. By Sample Type
10.2.4. By Products
10.2.5. By Circulating Biomarkers
10.2.6. By Disease Type
10.2.7. By Clinical Applications
10.2.8. By Country
10.2.9. Saudi Arabia Liquid Biopsy Market Outlook, 2016-2026F
10.2.9.1. Market Size & Analysis
10.2.9.1.1. Revenues
10.2.9.2. Market Share & Analysis
10.2.9.2.1. By Circulating Biomarkers
10.2.9.2.2. By Disease Type
10.2.9.2.3. By Clinical Applications
10.3. UAE Liquid Biopsy Market Outlook, 2016-2026F
10.3.1. Market Size & Analysis
10.3.1.1. Revenues
10.3.2. Market Share & Analysis
10.3.2.1. By Circulating Biomarkers
10.3.2.2. By Disease Type
10.3.2.3. By Clinical Applications

11. South Africa Liquid Biopsy Market Outlook, 2016-2026F

11.1. Market Size & Analysis
11.1.1. Revenues
11.2. Market Share & Analysis
11.2.1. By Circulating Biomarkers
11.2.2. By Disease Type
11.2.3. By Clinical Applications

12. Asia-Pacific Liquid Biopsy Market Outlook, 2016-2026F

12.1. Market Size & Analysis
12.1.1. Revenues
12.2. Market Share & Analysis
12.2.1. By Technology
12.2.2. By Usage
12.2.3. By Sample Type
12.2.4. By Products
12.2.5. By Circulating Biomarkers
12.2.6. By Disease Type
12.2.7. By Clinical Applications
12.2.8. By Country
12.2.8.1. China Liquid Biopsy Market Outlook, 2016-2026F
12.2.8.1.1. Market Size & Analysis
12.2.8.1.1.1. Revenues
12.2.8.1.2. Market Share & Analysis
12.2.8.1.2.1. By Circulating Biomarkers
12.2.8.1.2.2. By Disease Type
12.2.8.1.2.3. By Clinical Applications
12.2.8.2. India Liquid Biopsy Market Outlook, 2016-2026F
12.2.8.2.1. Market Size & Analysis
12.2.8.2.1.1. Revenues
12.2.8.2.2. Market Share & Analysis
12.2.8.2.2.1. By Circulating Biomarkers
12.2.8.2.2.2. By Disease Type
12.2.8.2.2.3. By Clinical Applications
12.2.8.3. Japan Liquid Biopsy Market Outlook, 2016-2026F
12.2.8.3.1. Market Size & Analysis
12.2.8.3.1.1. Revenues
12.2.8.3.2. Market Share & Analysis
12.2.8.3.2.1. By Circulating Biomarkers
12.2.8.3.2.2. By Disease Type
12.2.8.3.2.3. By Clinical Applications
12.2.8.4. South Korea Liquid Biopsy Market Outlook, 2016-2026F
12.2.8.4.1. Market Size & Analysis
12.2.8.4.1.1. Revenues
12.2.8.4.2. Market Share & Analysis
12.2.8.4.2.1. By Circulating Biomarkers
12.2.8.4.2.2. By Disease Type
12.2.8.4.2.3. By Clinical Applications
12.2.8.5. South East Asia Liquid Biopsy Market Outlook, 2016-2026F
12.2.8.5.1. Market Size & Analysis
12.2.8.5.1.1. Revenues
12.2.8.5.2. Market Share & Analysis
12.2.8.5.2.1. By Circulating Biomarkers
12.2.8.5.2.2. By Disease Type
12.2.8.5.2.3. By Clinical Applications

13. Global Liquid Biopsy Market List of Biopsies Approved by The Governments

14. Global Liquid Biopsy Market Policies, Regulations, Product Standards

14.1. The United States
14.2. European Union

15. Global Liquid Biopsy Market Intellectual Property Rights Insights

15.1. Patent Portfolio of Leading Players
15.2. Patent Filings, Registrations and Expiration

16. Global Liquid Biopsy Market Trends & Insights

17. Global Liquid Biopsy Market Dynamics

17.1. Growth Drivers
17.2. Challenges
17.3. Impact Analysis

18. Global Liquid Biopsy Market Hotspot & Opportunities

19. Competition Outlook

19.1. Competition Matrix
19.1.1. Product/ Solution Portfolio
19.1.2. Target Markets
19.1.3. Target End Users
19.1.4. Research & Development
19.1.5. Strategic Alliances
19.1.6. Strategic Initiatives
19.2. Competitor Capability Matrix
19.2.1. By Technology
19.2.2. By Sample Type
19.2.3. By Biomarker
19.2.4. By Application
19.3. Company Profiles of Top Companies (Business Description, Product Segments, Business Segments, Financials, Strategic Alliances/ Partnerships, Future Plans)
19.3.1. Bio-Rad Laboratories
19.3.2. Biocept Inc
19.3.3. Abcodia Ltd
19.3.4. Chronix Biomedical
19.3.5. Epic Sciences Inc
19.3.6. Hoffmann-La Roche AG
19.3.7. Cynvenio Biosystems, Inc.
19.3.8. GUARDANT HEALTH, INC
19.3.9. Illumina, Inc.
19.3.10. NeoGenomics Laboratories, Inc.
19.3.11. Menarini Silicon Biosystems, Inc.
19.3.12. Qiagen N.V.
19.3.13. Thermo Fisher Scientific
19.3.14. Personal Genome Diagnostics, Inc.
19.3.15. Qiagen N.V.

20. Disclaimer